Chronic Kidney Disease

According to published results, the use of gabapentinoids may be associated with an increased risk of hip fractures in older, frail patients and patients with chronic kidney disease.

Older women with chronic kidney disease who take denosumab may have a higher risk for emergently treated hypocalcemia compared with those treated with bisphosphonates, according to published data.

The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, but it could also lead to changes in the way clinicians treat the condition.

SAN DIEGO — Semaglutide was associated with lower risk for major kidney complications for adults with type 2 diabetes and chronic kidney disease without regard to baseline kidney function, data show.

SAN DIEGO — Black veterans who develop chronic kidney disease at a young age may be at a higher risk for eGFR decline than white veterans, according to data presented at Kidney Week.

Five years after receiving a complete response letter from the agency, Lexicon Pharmaceuticals brought sotagliflozin back before an FDA advisory panel to seek an indication to treat patients with type 1 diabetes and chronic kidney disease.

SAN DIEGO — Semaglutide, a GLP-1 receptor agonist approved for treatment of obesity and type 2 diabetes, improved kidney metrics for adults with overweight and obesity without diabetes, according study data.

SAN DIEGO — Compared with placebo, finerenone was associated with reductions in albuminuria and decreased risk of new-onset albuminuria among adults with heart failure, according to data from the FINEARTS-HF trial.

SAN DIEGO — Health care providers and advocates must confront social disparities among patients with kidney disease to improve the standard of care, American Society of Nephrology President Deidra C. Crews, MD, ScM, FASN, said.

Jessica Hergenreter has been appointed chief people officer at DaVita, where she will oversee engagement initiatives for the company, according to a press release.